Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 13/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554454 | 0.91 | CYP1A2 (0.46) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL17023818 | 0.91 | CFD (0.56) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29544847 | 0.91 | CFD (0.56) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29545064 | 0.91 | CFD (0.56) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL17023850 | 0.91 | CFD (0.56) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL17031920 | 0.90 | CFD (0.47) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL18591433 | 0.86 | CFD (0.47) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL17031916 | 0.86 | CFD (0.50) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL18591119 | 0.85 | CFD (0.48) | CFDCYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL18591434 | 0.84 | CFD (0.47) | CFDCYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | CFD 1/4885CYP1A2 3938/4885POLB 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.